BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 8318876)

  • 1. Urinary and erythrocyte polyamines during the evaluation of oral alpha-difluoromethylornithine in a phase I chemoprevention clinical trial.
    Pendyala L; Creaven PJ; Porter CW
    Cancer Epidemiol Biomarkers Prev; 1993; 2(3):235-41. PubMed ID: 8318876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine.
    Carbone PP; Douglas JA; Larson PO; Verma AK; Blair IA; Pomplun M; Tutsch KD
    Cancer Epidemiol Biomarkers Prev; 1998 Oct; 7(10):907-12. PubMed ID: 9796636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha-difluoromethylornithine as treatment for metastatic breast cancer patients.
    O'Shaughnessy JA; Demers LM; Jones SE; Arseneau J; Khandelwal P; George T; Gersh R; Mauger D; Manni A
    Clin Cancer Res; 1999 Nov; 5(11):3438-44. PubMed ID: 10589756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, placebo-controlled trial of low-dose alpha-difluoromethylornithine in individuals at risk for colorectal cancer.
    Love RR; Jacoby R; Newton MA; Tutsch KD; Simon K; Pomplun M; Verma AK
    Cancer Epidemiol Biomarkers Prev; 1998 Nov; 7(11):989-92. PubMed ID: 9829706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in polyamine metabolism during continuous intravenous infusion of alpha-difluoromethylornithine showing correlation of thrombocytopenia with alpha-difluoromethylornithine plasma levels.
    Ajani JA; Ota DM; Grossie VB; Levin B; Nishioka K
    Cancer Res; 1989 Oct; 49(20):5761-5. PubMed ID: 2507135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention.
    Meyskens FL; Gerner EW; Emerson S; Pelot D; Durbin T; Doyle K; Lagerberg W
    J Natl Cancer Inst; 1998 Aug; 90(16):1212-8. PubMed ID: 9719082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose de-escalation chemoprevention trial of alpha-difluoromethylornithine in patients with colon polyps.
    Meyskens FL; Emerson SS; Pelot D; Meshkinpour H; Shassetz LR; Einspahr J; Alberts DS; Gerner EW
    J Natl Cancer Inst; 1994 Aug; 86(15):1122-30. PubMed ID: 8028034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of alpha-difluoromethylornithine as a potential chemopreventive agent: tolerance to daily oral administration in humans.
    Creaven PJ; Pendyala L; Petrelli NJ
    Cancer Epidemiol Biomarkers Prev; 1993; 2(3):243-7. PubMed ID: 8318877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polyamine contents in rectal and buccal mucosae in humans treated with oral difluoromethylornithine.
    Boyle JO; Meyskens FL; Garewal HS; Gerner EW
    Cancer Epidemiol Biomarkers Prev; 1992; 1(2):131-5. PubMed ID: 1306095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary polyamine levels in cancer patients treated with D,L-alpha-difluoromethylornithine, an inhibitor of polyamine biosynthesis.
    Horn Y; Spigel L; Marton LJ
    J Surg Oncol; 1989 Jul; 41(3):177-82. PubMed ID: 2501593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I chemoprevention study of difluoromethylornithine in subjects with organ transplants.
    Carbone PP; Pirsch JD; Thomas JP; Douglas JA; Verma AK; Larson PO; Snow S; Tutsch KD; Pauk D
    Cancer Epidemiol Biomarkers Prev; 2001 Jun; 10(6):657-61. PubMed ID: 11401916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decarboxylated-S-adenosylmethionine excretion: a biochemical marker of ornithine decarboxylase inhibition by alpha-difluoromethylornithine.
    Haegele KD; Splinter TA; Romijn JC; Schechter PJ; Sjoerdsma A
    Cancer Res; 1987 Feb; 47(3):890-5. PubMed ID: 3100028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of difluoromethylornithine (DFMO) as a chemoprevention agent.
    Meyskens FL; Gerner EW
    Clin Cancer Res; 1999 May; 5(5):945-51. PubMed ID: 10353725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoprevention of oral carcinogenesis by DL-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor: dose-dependent reduction in 4-nitroquinoline 1-oxide-induced tongue neoplasms in rats.
    Tanaka T; Kojima T; Hara A; Sawada H; Mori H
    Cancer Res; 1993 Feb; 53(4):772-6. PubMed ID: 8428357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma.
    Saulnier Sholler GL; Gerner EW; Bergendahl G; MacArthur RB; VanderWerff A; Ashikaga T; Bond JP; Ferguson W; Roberts W; Wada RK; Eslin D; Kraveka JM; Kaplan J; Mitchell D; Parikh NS; Neville K; Sender L; Higgins T; Kawakita M; Hiramatsu K; Moriya SS; Bachmann AS
    PLoS One; 2015; 10(5):e0127246. PubMed ID: 26018967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine.
    Love RR; Carbone PP; Verma AK; Gilmore D; Carey P; Tutsch KD; Pomplun M; Wilding G
    J Natl Cancer Inst; 1993 May; 85(9):732-7. PubMed ID: 8478959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations in bone marrow and blood mononuclear cell polyamine and methylglyoxal bis(guanylhydrazone) levels: phase I evaluation of alpha-difluoromethylornithine and methylglyoxal bis(guanylhydrazone) treatment of human hematological malignancies.
    Maddox AM; Freireich EJ; Keating MJ; Haddox MK
    Cancer Res; 1988 Mar; 48(5):1367-73. PubMed ID: 3124958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoprevention of mouse colon tumors with difluoromethylornithine during and after carcinogen treatment.
    Tempero MA; Nishioka K; Knott K; Zetterman RK
    Cancer Res; 1989 Nov; 49(21):5793-7. PubMed ID: 2507137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel lysine-spermine conjugate inhibits polyamine transport and inhibits cell growth when given with DFMO.
    Weeks RS; Vanderwerf SM; Carlson CL; Burns MR; O'Day CL; Cai F; Devens BH; Webb HK
    Exp Cell Res; 2000 Nov; 261(1):293-302. PubMed ID: 11082299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers.
    Fabian CJ; Kimler BF; Brady DA; Mayo MS; Chang CH; Ferraro JA; Zalles CM; Stanton AL; Masood S; Grizzle WE; Boyd NF; Arneson DW; Johnson KA
    Clin Cancer Res; 2002 Oct; 8(10):3105-17. PubMed ID: 12374678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.